Skip to main content
. 2022 Mar 7;13(3):6113–6125. doi: 10.1080/21655979.2022.2035124

Figure 1.

Figure 1.

NCAPG was over-expressed in LUAD tissues and cell lines and was associated with patients’ poor prognosis. (a) the mRNA expression level of NCAPG in pan-cancer tissues and corresponding normal specimens by using the TIMER web tool. ***, p < 0.001. (b) the mRNA expression level of NCAPG in LUAD patient tissues (N = 483) and normal samples (N = 347) through GEPIA online tool. *, p < 0.05. (c) NCAPG mRNA levels at different stages of LUAD. (d) the overall survival time of LUAD patients with high or low expression level of NCAPG were analyzed by GEPIA. Logrank p = 0.002. (e) display image of IHC results of NCAPG in LUAD tissue (N = 60) and normal tissue (N = 30). (f) statistical analysis of IHC results in (E). **, p < 0.01. (g) analysis of survival probability of 60 cases of LUAD patients with different NCAPG expression level. p = 0.00086. (h-i) BEA-2B, A549, H1299, HCC827 and H1792 cells were harvested and subjected to Western blotting and RT-PCR analysis. Results presented as Mean ± SD (N = 3). **, p < 0.01, ***, p < 0.001, ****, p < 0.0001. (j) IF was performed to clarify the location of NCAPG in A549 cell. DAPI was used to label the nucleus.